Sylvester Comprehensive Cancer Center Researcher Presents Phase 1 Trial for Neuroendocrine Tumors at ASCO
Summary
- A Sylvester researcher will present a phase I clinical trial combining immunotherapy and an oncolytic virus at the ASCO annual meeting.
- The study targets aggressive neuroendocrine tumors that often resist standard immunotherapy.
- The trial is actively recruiting patients nationwide to advance early-phase cancer research.
For patients with aggressive neuroendocrine tumors, treatment options are often limited and outcomes uncertain. At this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, a researcher at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, will share early-stage research aimed at changing that trajectory.
Chinmay Jani, M.D., Sylvester chief fellow in hematology and oncology, will present his team’s ongoing phase I clinical trial at the 2026 ASCO conference. The study looks at escalating doses of a drug combination that may benefit patients with high-grade neuroendocrine tumors.
High-grade neuroendocrine cancer is a rare and aggressive disease that has seen limited progress in treatment. It’s relatively uncommon and hasn’t benefited from substantial research investment. For many patients, standard chemotherapy remains one of the only available options.
This Sylvester trial introduces a different strategy. Participants are treated with a combination of immunotherapy medications and a tumor-targeting “oncolytic” virus delivered directly into the tumors. The trial reflects Sylvester’s commitment to innovative, early-phase, investigator-initiated clinical trials designed to advance cancer treatment. That commitment includes sustained investment in clinical research infrastructure, including the Kenneth C. Griffin Cancer Research Building, which opened in fall 2025.
Targeting Aggressive Neuroendocrine Tumors
Dr. Jani, who will join the Sylvester faculty this summer in phase I experimental therapeutics and thoracic oncology, is focusing on high-grade neuroendocrine tumors, including small cell lung cancer (SCLC). These rare and aggressive cancers often prove fatal within one to two years of diagnosis.
“Immunotherapy has revolutionized cancer treatment,” said Dr. Jani. “But it still has a lot of issues, including resistance, and many patients are non-responders. This trial is about improving immunotherapy.”
Checkpoint inhibitors, a type of immunotherapy, have been highly effective in many cancers. But many high-grade neuroendocrine tumors do not respond. These tumors can evade immune recognition, preventing checkpoint inhibitors from effectively activating immune cells within the tumor microenvironment.
The goal of the trial, Dr. Jani explained, is to determine whether tumors respond more effectively to a combination of two immunotherapy drugs, nivolumab and ipilimumab, when delivered alongside Seneca Valley virus (SVV-001).
SVV-001 selectively grows inside tumors and may disrupt them in a way that exposes cancer-specific molecules, allowing immune cells to better recognize and attack the disease.
“Many tumors evade immune detection. This study evaluates whether SVV-001 can expose cancer cells and enhance the effectiveness of checkpoint inhibitors,” said Gilberto Lopes, M.D., Sylvester’s chief of medical oncology, associate director and medical director for international affairs. Dr. Lopes is also a professor of medical oncology at the Miller School.
A Key Biomarker
In a previous study published in March 2026, the team identified tumor endothelial marker 8 (TEM8), a biomarker expressed only in cancer cells.
“There’s no expression at all in normal organs such as lung, ovarian, pancreas, stomach, uterus, breast, colon, etc. However, in patients whose tumors express TEM8, the outcomes are poor. It increases tumor aggressiveness and metastasis, as well,” said Dr. Jani.
SVV-001 targets TEM8, allowing the therapy to attack aggressive cancer cells more precisely. Using next-generation sequencing, the researchers will evaluate how TEM8 expression levels may influence patient outcomes.
New Trial Actively Recruiting Patients
The trial officially launched in 2025 and has completed its first three dose levels. During this phase, patients received a single dose of SVV-001 followed by immunotherapy. No dose level tested to date has resulted in severe treatment-related side effects.
In the next phase of the study, participants will receive up to six doses of SVV-001 injections followed by immunotherapy. After completion, the study will expand at the optimal dose level.
Researchers are continuing to enroll patients as the trial advances through early study phases.
While the scientists acknowledge the research is still in its early stages, the study reflects a growing effort at Sylvester to explore experimental therapeutics for cancers that have long lacked effective treatment options, offering cautious optimism rooted in science and collaboration.
“If you have a patient who could be potentially eligible in the future, we prefer to evaluate this patient early. If this patient is already screened and their current treatment eventually stops working, we can enroll them more quickly,” said Peter Hosein, M.D., Sylvester researcher and professor of medical oncology at the Miller School.
A few weeks may make a significant difference in outcomes, he noted.
More from Sylvester Comprehensive Cancer Center
New study finds U.S. mesothelioma rates falling but cases rising, with gender disparities and geographic hotspots highlighting ongoing asbestos risks.
Sylvester’s Zubrod Memorial Lecture honored cancer research leaders, rising trainees and discoveries shaping the future of oncology.
Dr. Chinmay Jani used serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure.
Sylvester Comprehensive Cancer Center researchers say the cost of cancer drugs can prevent patients from getting the care they need.
Tags: ASCO 2026, cancer research, clinical trials, Dr. Chinmay Jani, Dr. Gilberto Lopes, immunotherapy, lung cancer, neuroendocrine cancer, Neuroendocrine Tumor Program, Newsroom, small cell lung cancer, Sylvester Comprehensive Cancer Center